ALCRESTA - Key Persons

Job Titles:

• Chief Legal and Compliance Officer
• Secretary

Bill Scheinler is Chief Legal and Compliance Officer and Secretary at Alcresta Therapeutics. He brings years of experience as a leader in public and private medical device and pharmaceutical companies, and as a specialist in compliance, contracting, mergers and acquisitions, and licensing. Bill was previously Vice President, Associate General Counsel for Ikaria, Inc., where he helped transform a business that was expected to face generic competition into a durable customer service-focused franchise with growing revenues, resulting in a five-fold increase in enterprise value. Among his responsibility at Ikaria were driving and supporting multiple in-licensing and product acquisition/divestiture transactions, the spin-out of the company's R&D business to a stand-alone public company, developing effective and compliant business sustainability strategies, resolving complex, high value commercial disputes, and overseeing company contracting, including contracts with customers and key suppliers. Prior to joining Ikaria, Bill was Associate General Counsel at VIASYS Healthcare, Inc., a public healthcare technology company with four business units focused in respiratory care, neurology, medical disposables, surgical products, and orthopedics. At VIASYS, he supported the company's global expansion strategy, including the acquisition of 11 companies to grow the company's revenues by four times and enterprise value by more than three times. Before joining VIASYS, Bill was in the business and finance group at Morgan, Lewis & Bockius LLP, with a focus in technology transactions, licensing, outsourcing, supply and distribution arrangements, and mergers and acquisitions. Bill holds a J.D. from Temple University - James E. Beasley School of Law and an M.A. in International Policy Analysis from Middlebury Institute of International Studies at Monterey.

Job Titles:

• Chief Operating Officer
• Chief Operations Officer

Chris Parrish is the Chief Operations Officer of Alcresta Therapeutics. He joins Alcresta with more than 25 years of biotech and medical device industry experience. Prior to joining Alcresta, Chris was Vice President of Manufacturing at Vericel Corporation, an autologous cell therapy company, where during his tenure he also led quality and worked in research and development. In addition to leading Manufacturing Operations through completion of clinical trials, Chris has also supported product launch and commercial success of cell therapy products. Chris started his career with Pfizer as a scientist in research and development and quality.

Job Titles:

• Chairman of the Board
• Chief Executive Officer

Daniel Orlando is the Chief Executive Officer of Alcresta Therapeutics. He joins the team with more than 18 years of executive management and corporate development experience leading organizations through rapid growth in the development, manufacturing and commercialization of therapeutics and biologics. Prior to joining Alcresta Therapeutics, Daniel was most recently the Chief Operating Officer of Vericel Corporation, an autologous cell therapy company, which purchased the cell therapy and regenerative medicine business unit from Sanofi Genzyme. During his tenure, he led every function at Vericel, most recently, Sales, Marketing, Manufacturing, Engineering, and Research & Development. Before joining Vericel, Daniel was one of Takeda North America's early employee's and held executive positions in Business Development, Marketing, and Sales as well as similar developmental roles at Abbott Laboratories. Daniel holds a BA in Economics with Honors from the University of Florida and an MBA from Florida Atlantic University.

Job Titles:

• Chairman of the Board of Avalign Technologies
• Operating Partner, Linden Capital Partners

Mr. Waaser is a veteran operator and medical products executive who spent the first 18 years of his career with DuPont in multiple business units and functions. In the two decades following his career at DuPont, Mr. Waaser held top leadership positions at a number of healthcare businesses, including CEO of Systagenix, a leveraged buy-out of Johnson & Johnson's wound care unit; President of Teleflex Medical; CEO of Hill-Rom; and COO of Sterling Diagnostic Imaging, a leveraged buy-out of DuPont's medical imaging assets. Mr. Waaser most recently served as Chief Executive Officer of NuSil Technology, a manufacturer of specialty silicones for life sciences and advanced technology applications, leading the business to significant growth and a successful merger in late 2016. He is currently an Operating Partner with Linden Capital Partners. Mr. Waaser currently serves as chairman of the board of Avalign Technologies and served on the boards of Flexan, NuSil, Systagenix, and Advamed. He holds a Bachelor of Science in Nuclear Engineering from Mississippi State University and a Master of Engineering from University of South Carolina.

Job Titles:

• Principal at HealthQuest Capital

Jared Teo is currently a Principal at HealthQuest Capital. HealthQuest is a venture growth equity fund, investing in healthcare innovation across most of the healthcare spectrum: medical technologies, diagnostics, digital health, and innovative services. Prior to joining HealthQuest, he was an operator at medical device companies with successful exits and an investment banker at Goldman Sachs. Mr. Teo has 14 years of healthcare industry experience (7 years investing), and currently also serves as a board member at HealthQuest portfolio companies CleanSlate and Etairos, and a board observer at Ajax Health. The foundation of Mr. Teo's experience is in medical device R&D. At FoxHollow Technologies (acquired by eV3), Kerberos Proximal Solutions (acquired by FoxHollow) and CryoCor (acquired by Boston Scientific), Mr. Teo led the conception, development and commercialization of innovative devices in several therapeutic areas, first as an R&D Engineer and later as an R&D Project Manager. At Goldman Sachs, Mr. Teo advised clients across the life sciences, diagnostics and medical device industries on M&A transactions and public equity/debt financings. Mr. Teo was responsible for complex financial analyses and day-to-day transaction execution. Mr. Teo received a B.S. in Bioengineering from UC San Diego and an MBA from The Wharton School at the University of Pennsylvania. He is an aspiring photographer and fitness enthusiast.

Job Titles:

• Chief Commercial Officer

Jason Weiner is the Chief Commercial Officer of Alcresta Therapeutics. He joins the team with more than 17 years of industry and strategy consulting experience in the biopharmaceutical industry. Prior to Alcresta, Jason was the Vice President of Marketing and Market Access at Vericel Corporation, an autologous cell therapy company, where during his tenure he led all marketing and market access related activities for the cell therapy and regenerative medicine franchise. Included was the expansion and build-out of the commercial team and development of an innovative patient access and distribution program. Jason held developmental Sales roles at Pfizer and Astellas before leading strategy engagements as a consultant at Charles River Associates where he advised on issues related to customer engagement, payer marketing, drug launches, physician research, sales force alignment, market access, and pricing strategy. Jason holds a BA in History from Union College and an MBA from Boston College.

Job Titles:

• Member of the Alcresta Board of Directors
• Partner
• Partner, Linden Capital Partners

Piyush Shukla is a Partner with Linden Capital Partners, a Chicago headquartered healthcare-only private equity firm. Prior to Linden, Mr. Shukla worked in the healthcare team at Warburg Pincus in London, and before that in the Principal Investments Area at Barclays Capital. Mr. Shukla began his career with Arthur Andersen where he qualified as a Chartered Accountant with the Institute of Chartered Accountants in England and Wales. Mr. Shukla holds a Master of Arts with honors in Natural Sciences (Astrophysics) from Cambridge University and an MBA from The Wharton School, University of Pennsylvania.

Job Titles:

• Member of the Alcresta Board of Directors
• Principal at Linden Capital Partners

Prab Chawla is a Principal at Linden Capital Partners and has been involved in principal investing and investment banking since 2010. Prior to joining Linden, he worked for the private equity arm of the World Bank, where he evaluated and executed investments in various emerging markets. Previously, Mr. Chawla was at KRG Capital Partners, where he focused on private equity opportunities across healthcare, consumer, business services, and manufactured products. He began his career in investment banking at Credit Suisse, where he worked in the Mergers & Acquisitions Group in New York. Mr. Chawla holds a BA in Economics, with honors, from Northwestern University and an MBA from Harvard Business School.

Job Titles:

• Member of the Alcresta Board of Directors
• Chairman of the Board, Operating Partner, Linden Capital Partners

Mr. Labrum is an experienced operator and leader in healthcare distribution and medical device sectors who began his career with American Hospital Supply and spent over 25 years with Baxter International (NYSE: BAX), Allegiance Healthcare, and Cardinal Health (NYSE: CAH). Mr. Labrum's career has been distinguished by leadership roles in sales, operations, and manufacturing in addition to execution and integration of several mergers and acquisitions. Most recently, Mr. Labrum was CEO of Fenwal, Inc., a private equity backed spinout of Baxter's device business focused on blood technologies. Mr. Labrum led Fenwal for six years prior to a successful sale of the company to Fresenius SE & Co. Mr. Labrum currently serves on the boards of Ortho-Clinical Diagnostics, Wright Medical, Aptalis, and Suture Express. He holds a Bachelor of Science in Business Administration from Utah State University.